Skip to main content
Clinical Trials/NL-OMON23641
NL-OMON23641
Recruiting
Not Applicable

Early detection of cardiac dysfunction in childhood cancer survivors; a DCOG LATER study

Princess Maxima Center for pediatric oncology, Amsterdam UMC (AMC), Radboudumc, SKIO0 sites2,200 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiotoxicity in childhood cancer survivors
Sponsor
Princess Maxima Center for pediatric oncology, Amsterdam UMC (AMC), Radboudumc, SKIO
Enrollment
2200
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Princess Maxima Center for pediatric oncology, Amsterdam UMC (AMC), Radboudumc, SKIO

Eligibility Criteria

Inclusion Criteria

  • Eligible survivors are 5\-year childhood cancer survivors (CCS) diagnosed before the age of 18 years, between 1/1/1963 and 12/31/2001 with a malignancy according to the third edition of the International Classification of Childhood Cancer. We only included CCS who were living in the Netherlands at the time of childhood cancer diagnosis and who were treated in one of the Dutch pediatric oncology/hematology centers (Academic Medical Center Amsterdam, VU University Medical Center, Leiden University Medical Center, Erasmus Medical Center, University Medical Center Groningen, Radboudumc, and University Medical Center Utrecht). This study will include 4 risk groups; risk group 1: CCS who have received anthracyclines, mitoxantrone, or irradiation to the heart region; risk group 2 (max n\=100\): cyclophosphamide only (no anthracyclines, mitoxantrone, or irradiation to the heart region, ifosfamide or vincristine); risk group 3 (max n\=100\): ifosfamide only (no anthracyclines, mitoxantrone, or irradiation to the heart region, cyclophosphamide or vincristine); risk group 4 (max n\=100\): vincristine only (no anthracyclines, mitoxantrone, or irradiation to the heart region, ifosfamide or cyclophosphamide), irrespective current age. For the comparison group 500 healthy siblings will be included.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials